Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis

Early and Long-term Clinical Efficacy and Local Tissue and Peripheral Immune Changes Following Dupilumab Treatment in Prurigo Nodularis Patients

With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.

Inclusion Criteria:

• Adult patients with moderate-to-severe prurigo nodularis starting dupilumab treatment

Exclusion Criteria:

• Unwilling to participate in the BioDay registry
• (For translational endpoints only) Unwilling to participate in UMC Utrecht Biobank